Medical Management of Obesity
Am Fam Physician. 2000 Jul 15;62(2):419-426.
Obesity is one of the most common medical problems in the United States and a risk factor for illnesses such as hypertension, diabetes, degenerative arthritis and myocardial infarction. It is a cause of significant morbidity and mortality and generates great social and financial costs. Obesity is defined as a body mass index greater than 30. Many patients accomplish weight loss with diet, exercise and lifestyle modification. Others require more aggressive therapy. Weight loss medications may be appropriate for use in selected patients who meet the definition of obesity or who are overweight with comorbid conditions. Medications are formulated to reduce energy intake, increase energy output or decrease the absorption of nutrients. Drugs cannot replace diet, exercise and lifestyle modification, which remain the cornerstones of obesity treatment. Two new agents, sibutramine and orlistat, exhibit novel mechanisms of action and avoid some of the side effects that occurred with earlier drugs. Sibutramine acts to block uptake of serotonin, norepinephrine and dopamine, while orlistat decreases fat absorption in the intestines.
An estimated 97 million adults in this country are obese, representing 31.3 percent of men and 34.7 percent of women.1 The costs to society are both direct and indirect, and include increased medical expenses, loss of productivity in the workplace, disability claims and job discrimination. Approximately $30 billion is spent on weight loss remedies in the United States each year. Treatment of obesity and diseases directly related to it accounts for 5 to 7 percent of total health care costs annually.2
Family physicians must treat any conditions associated with obesity while working with patients on methods to achieve and maintain weight loss.
Definition of Obesity
The World Health Organization has formulated an index for defining obesity. Known as the body mass index (BMI), it is based on the patient's height in meters and weight in kilograms: BMI = weight in kilograms ÷ (height in meters)2 (Figure 1). This classification works for all patients except those at the extremes of height or muscle mass, where body proportions affect the calculation.3
The International Obesity Task Force has stratified patients into different classes of obesity (Table 1). A BMI of 18.5 to 24.9 is defined as normal, a BMI of 25.0 to 29.9 as overweight and a BMI of 30 or greater as obese. In the United States, obesity was once defined as the top 15 percent of the population's weight for a given height, but this calculation does not adjust for the changing height and weight characteristics of the country's population.3 It is important to remember that the BMI is not a measure of body composition; different groups of persons with the same BMI might have higher or lower levels of body fat or muscle mass.
TABLE 1 Classification of Overweight and Obesity in Adults
Classification of Overweight and Obesity in Adults
|Classification*||BMI (kg per m2)†||Risk of comorbidities‡|
18.5 to 24.9
25.0 to 29.9
30.0 to 34.9
35.0 to 39.9
BMI = body mass index.
*—International Obesity Task Force (IOTF) classification as modified by World Health Organization (1997).
†—Values are age-independent and the same for both sexes.
‡—Both BMI and a measure of fat distribution (waist circumference or waist-to-hip ratio, etc.) are important in calculating the risk of obesity comorbidities.
Adapted with permission from James WP. What are the health risks? The medical consequences of obesity and its health risks. Exp Clin Endocrinol Diabetes 1998;106(suppl 2):1.
The physician must consider the patient's risk status when selecting appropriate therapy for obesity. Coronary heart disease, type 2 diabetes (formerly known as non–insulin-dependent diabetes) and sleep apnea are regarded as high-risk conditions that increase the likelihood of morbidity and mortality. Other risk factors associated with obesity are listed in Table 2. Patients with three or more risk factors have a high absolute risk of morbidity and mortality from obesity. Patients with two or more risk factors and a BMI of 27.0 to 29.9 should be considered for weight loss treatment.4
TABLE 2 Risk Factors Associated with Increased Morbidity and Mortality in Obese Persons
Risk Factors Associated with Increased Morbidity and Mortality in Obese Persons
Coronary artery disease
Type 2 diabetes
Other risk factors
Age > 45 in men
Age > 55 or postmenopausal in women
LDL > 160 mg per dL (4.14 mmol per L)
HDL < 35 mg per dL (0.91 mmol per L)
Impaired fasting glucose
Family history of premature coronary artery disease
LDL = low-density lipoprotein cholesterol; HDL = high-density lipoprotein cholesterol.
Information from Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. NIH/National Heart, Lung, and Blood Institute Obesity Education Initiative. WMJ 1998;97:20–37.
Etiology of Obesity
Obesity is caused by a constellation of factors including excessive energy intake (food), insufficient energy output (exercise, low resting metabolic rate [RMR]), genetic predisposition, low fat oxidation rate, low sympathetic activity, low plasma leptin level, environment favoring weight gain, psychologic stressors and lower socioeconomic status.4,5 The goal of obesity treatment is to exert a negative energy balance on the system by reducing energy input or increasing energy output, or both. A low RMR for a given body mass is a risk factor for weight gain.6
RMR is influenced by aerobic capacity and fat-free weight, an indirect measure of muscle mass. RMR decreases with advancing age. It accounts for 60 to 75 percent of the daily energy expenditure and represents a major component of energy balance.7 Evidence suggests that a low RMR may be due to genetic variation involving sympathetic activity, thyroid activity, β3-receptor sensitivity and sodium, potassium, and adenosine triphosphatase (Na+, K+-ATPase) enzyme activity.6
A feedback loop for weight loss has been postulated to explain why patients can generally lose only 10 to 15 percent of their body weight. As weight is lost by restricted energy intake, fat cells shrink, reducing expression of leptin, a product of the ob gene. As leptin levels fall, metabolic rate decreases, and appetite increases, thereby impeding further weight loss.8 Environmental factors also influence weight. Studies have shown an inverse relationship between socioeconomic status and obesity.9 Sedentary lifestyle is clearly a risk factor as well.
Treatment of Obesity
DIET, EXERCISE, LIFESTYLE CHANGES
Proper diet, exercise and behavior modification are the foundation of treating obesity. Pharmacologic treatment of obesity should be considered in patients who have comorbid conditions and in whom diet and exercise alone have proved insufficient.
Patients with no comorbid conditions and a BMI of 25.0 to 29.9 should not receive medication for obesity. Patients with a BMI of 30 or greater with no complications and those with a BMI of 27.0 to 29.9 and two comorbid conditions may be candidates for pharmacologic therapy. A treatment algorithm is presented in Figure 2.
Many different agents are available for the medical management of obesity. They can be classified by their mechanism of action: drugs that reduce energy intake, drugs that increase energy expenditure and nutrient-partitioning agents. Although some of these medications show promise, no long-term outcome studies have assessed their effect on overall morbidity and mortality.
Drugs That Reduce Energy Intake. Two classes of anorectic drugs are currently available in the U.S.: noradrenergic agents and serotonergic agents. Within the noradrenergic class, diethylpropion (Tenuate), mazindol (Sanorex), phenylpropanolamine (Dexatrim), phentermine (Fastin) and phendimetrazine (Bontril) are characteristic medications. These medications preserve the anorectic effects of amphetamines with weaker stimulant activity and little abuse potential.
All of the noradrenergic drugs except phenylpropanolamine act through a centrally mediated pathway in the hypothalamus that causes anorexia.10 Phenylpropanolamine, a racemic mixture of norephedrine esters, causes a release of norepinephrine throughout the body and stimulates hypothalamic adrenoreceptors to reduce appetite.10 It is a common ingredient of cold formulations. Noradrenergic agents provide modest, short-term weight loss when combined with dietary programs.1 No studies have evaluated the long-term use of these medications, and evidence exists that weight gain recurs when the agent is discontinued.
Side effects for this class of drugs include insomnia, nervousness, irritability, headache, nausea and constipation. Mazindol and phentermine have the potential to increase blood pressure and precipitate angina in some persons and should be used with caution in patients with cardiac risk factors.9 Phenylpropanolamine is believed by some to cause an elevation in blood pressure,11 although others disagree.9 Diethylpropion is thought to have a more tolerable side effect profile. Abuse potential is extremely low for these agents.
Serotonergic agents include fenfluramine (Pondimin) and dexfenfluramine (Redux). Fenfluramine and dexfenfluramine stimulate release of serotonin and inhibit its reuptake. They have been shown to cause weight loss in obese persons.9 These medications were withdrawn from the market after valvular heart disease was reported in a small number of patients using the combination of fenfluramine and phentermine.8
Sibutramine (Meridia) is a novel agent that inhibits the reuptake of serotonin, norepinephrine and dopamine. It does not stimulate secretion of serotonin.9 The drug produces weight loss by its anorectic effect and, possibly, by stimulating thermogenesis (i.e., increasing metabolic rate). It is metabolized by the cytochrome P450 enzyme system to two active metabolites.12 Sibutramine's effect on food intake is caused by increased noradrenergic and serotonergic activity in the central nervous system. In laboratory animals, the drug decreases time spent eating and increases time spent resting, maintaining the normal physiologic pattern of eating, resting and activity. This differs from amphetamine-class drugs, which cause eating and resting behavior to be replaced by increased locomotor activity, disrupting the normal cycle.13
Studies have shown that active weight loss occurs for the first six months of sibutramine use and can be maintained for up to one year with continued treatment. At the initial dosage of 10 mg daily, 40 percent of subjects lost 5 percent of their baseline weight, and 20 percent lost 10 percent of their baseline weight. When the dosage was increased to 15 mg daily, significantly more patients in each category lost weight.12 Another study14 demonstrated significant, dose-dependent weight loss over 24 weeks with sibutramine; however, like other studies, it showed that weight gain occurs with discontinuation of the drug. When compared with dexfenfluramine, sibutramine was found to produce significantly greater weight loss over a period of 12 weeks, with a more tolerable side effect profile.15
Sibutramine therapy has also been studied in patients with diabetes. In one study of patients with type 2 diabetes,16 sibutramine produced significant weight loss compared with placebo, but less weight loss than in non-diabetic patients. Interestingly, the treated group also experienced a decrease in glycosylated hemoglobin levels, although it is not known whether this loss was related directly to sibutramine or was a result of the patients' overall weight loss. Other studies have shown that sibutramine can reduce hyperinsulinemia and increase insulin-mediated glucose disposal, resulting in decreased insulin resistance.17 Whether this effect is caused by sibutramine directly or is a result of reduced adiposity in the subjects is unclear.
Adverse effects attributed to sibutramine include headache, insomnia, constipation and dry mouth. Increases in blood pressure (mean 2 mm Hg in both systolic and diastolic blood pressure) and pulse rate (3 to 6 beats per minute) may also occur. Patients with cardiac conditions should be given this drug with caution.16 The manufacturer advises against giving sibutramine to patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke. Sibutramine use should also be avoided in patients taking other serotonergic medications, including selective serotonin reuptake inhibitors (SSRIs) and serotonin agonists, lithium, meperidine, fentanyl, monoamine oxidase inhibitors (MAOIs) and dextromethorphan.18 Laboratory studies have suggested that sibutramine's action may be partially inhibited by noradrenergic antagonists (alpha and beta blockers) or serotonergic agents.14
Because the cytochrome P450 system is involved in the metabolism of the drug, patients with severe hepatic disease should be given sibutramine with caution. Because the drug inhibits reuptake of serotonin but does not stimulate secretion, some feel that the risk of heart-valve lesions is low.19–21 Primary pulmonary hypertension, which is associated with other centrally acting serotonergic weight loss medications, has not been reported in patients treated with sibutramine.9,10 In clinical trials, the drug has been determined to have no potential for abuse.22 It is classified as a schedule IV drug in the Federal Controlled Substances Act, which means that it has a low potential for abuse and that abuse may lead to limited physical and psychologic dependence.
Nutrient Partitioning. Orlistat (Xenical) is a weight loss medication of novel mechanism. A lipase inhibitor, it acts in the gastrointestinal tract to decrease fat absorption. The drug is not absorbed but instead inhibits pancreatic and gastric lipases, thus reducing triglyceride hydrolysis.10 Unabsorbed triglycerides and cholesterol are excreted in feces. Studies have shown weight loss of 8.5 percent at one year compared with 5.4 percent for placebo.10
In a randomized, double-blind, placebo-controlled trial,23 orlistat-treated patients had significantly more weight loss at one year; most patients maintained weight loss at two years with continuation of the drug. These findings were reproduced in a later study in which orlistat produced significant weight loss at one year.24 Patients lost an average of 8.8 kg in the first year, compared with 5.8 kg in the placebo group. Patients taking orlistat subsequently regained 3.2 kg in the second year compared with 5.6 kg in the placebo group. Unfortunately, the study had a relatively high dropout rate, which could make it difficult to apply to the general population. In this study,24 orlistat also decreased total serum cholesterol and low-density lipoprotein (LDL) levels but did not change the HDL/LDL ratio. LDL was reduced by 8 mg per dL, and total cholesterol was reduced by 11 mg per dL over a two-year period, which was significantly different from the result achieved with placebo.
Side effects of orlistat include steatorrhea, flatus, fecal incontinence and oily spotting. These effects are more dramatic with the consumption of fatty foods and may contribute to weight loss by discouraging dietary indiscretion. In two randomized, controlled studies,23,24 gastrointestinal side effects were considered mild to moderate and improved in the second year of treatment.
The package insert warns of changes in coagulation parameters in patients being treated with warfarin (Coumadin), because of the possibility of decreased vitamin K absorption. In one study,24 plasma concentrations of fat-soluble vitamins were lower in orlistat-treated patients than in the placebo group, but they remained within the reference range. Other studies have shown a slight decrease in fat-soluble vitamin levels in orlistat-treated patients.23,25 The manufacturers recommend vitamin supplementation, although not within two hours of orlistat administration. The drug is contraindicated in patients with chronic malabsorption syndrome or cholestasis. A comparison of sibutramine and orlistat is presented in Table 3.
TABLE 3 Summary of New Weight Loss Medications
Summary of New Weight Loss Medications
|Medication||Mechanism of effect||Side effects||Dosage||Cost|
Reuptake inhibitor of serotonin, norepinephrine and dopamine
Elevated blood pressure, tachycardia, headache, insomnia, constipation, dry mouth
10 mg daily initially; can increase to 15 mg daily after 4 weeks in nonresponders
Reversible lipase inhibitor
Fecal incontinence, oily spotting, flatulence, vitamin malabsorption
120 mg three times daily with meals
*—Estimated cost to the pharmacist based on average wholesale prices (rounded to the nearest dollar), for one month of therapy at the lowest usual dosage, in Red Book. Montvale, N.J.: Medical Economics, 1999. Cost to the patient may be greater, depending on prescription filling fee.
†—Average wholesale price (rounded to the nearest dollar), for one month of therapy at the lowest usual dosage, from Acculine, a wholesale information database.
Agents to Increase Energy Expenditure. Agents that increase energy expenditure are scarce. The search for a thermogenic medication that has a tolerable side effect profile has yielded few drugs, and none is recommended for weight loss treatment.
Ephedrine and the xanthines, such as caffeine and theophylline, increase metabolic rate. Studies have demonstrated their efficacy as short-term weight loss medications, but the risk of cardiac complications from hypertension, increased heart rate, increased myocardial oxygen consumption and increased cardiac output limit their clinical use.10 Thyroid hormone also increases the metabolic rate, but it can cause tachycardia and is associated with accelerated protein loss. Moreover, its effect on weight loss is minimal. It is not recommended as a weight loss medication.
Other Drugs. Leptin, a hormone produced by fat cells, controls food intake and energy expenditure. In obese persons who are losing weight without medications, a decrease in weight is associated with a decrease in circulating levels of leptin, suggesting its role in weight homeostasis. Obese patients with high leptin levels are thought to have peripheral leptin resistance secondary to the down-regulation of leptin receptors.19 It was hoped that administering leptin would stimulate weight loss, but peripherally administered leptin has been found to have no effect.
Cholecystokinin is a peptide that activates gastric vagal fibers, triggering satiety. Administration of cholecystokinin decreases food intake, but the agent must be administered parenterally, and no safety studies have been performed.9
Surgical Intervention. In some persons, weight loss is crucial because of coexisting conditions such as sleep apnea, cardiovascular disease or diabetes. When medical management and lifestyle changes prove insufficient, surgical intervention may be considered. Vertical banded gastroplasty and Roux-en-Y gastric bypass can result in dramatic weight loss of up to 25 percent. Surgical mortality can be as low as 1 percent.26 It is important to remember, however, that a weight loss of even 5 percent, achieved with diet modification, exercise and medical therapy, can lead to substantial improvements in other metabolic and cardiopulmonary conditions. The risks of surgery must be taken seriously.
1. Poston WC 2d, Foreyt JP, Borrell L, Haddock CK. Challenges in obesity management. South Med J. 1998;91:710–20.
2. Seidell JC. Societal and personal costs of obesity. Exp Clin Endocrinol Diabetes. 1998;106(suppl 2):7–9.
3. James WPT. What are the health risks? The medical consequences of obesity and its health risks. Exp Clin Endocrinol Diabetes. 1998;106(suppl 2):1–6.
4. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. NIH/National Heart, Lung, and Blood Institute Obesity Education Initiative. WMJ. 1998;97:20–37.
5. Astrup A, Lundsgaard C. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice. Exp Clin Endocrinol Diabetes. 1998;106(suppl 2):29–34.
6. Astrup A, Hansen DL, Lundsgaard C, Toubro S. Sibutramine and energy balance. Int J Obesity Relat Metab Disord. 1992;22:S30–8S42.
7. Poehlman ET, Berke EM, Joseph JR, Gardner AW, Katzman-Rooks SM, Goran MI. Influence of aerobic capacity, body composition, and thyroid hormones on the age-related decline in resting metabolic rate. Metabolism. 1992;41:915–21.
8. Aronne LJ. Modern medical management of obesity: the role of pharmaceutical intervention. J Am Diet Assoc. 1998;98(10 suppl 2):S23–6.
9. Weiser M, Frishman WH, Michaelson MD, Abdeen MA. The pharmacologic approach to the treatment of obesity. J Clin Pharmacol. 1997;37:453–73.
10. Finer N. Present and future pharmacologic approaches. Br Med Bull. 1997;53:409–32.
11. Lake CR, Gallant S, Masson E, Miller P. Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports. Am J Med. 1990;89:195–208.
12. Van Gaal LF, Wauters MA, De Leeuw IH. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment. Exp Clin Endocrinol Diabetes. 1998;106 (suppl 2):35–40.
13. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord. 1997;21(suppl 1):S25–9.
14. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res. 1996;4:263–70.
15. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. A comparison of sibutramine and dexfenfluramine in the treatment of obesity. Obes Res. 1998;6:285–91.
16. Lean MEJ. Sibutramine: a review of clinical efficacy. Int J Obes Relat Metab Disord. 1997;21(suppl 1):S30–6.
17. Day C, Bailey CJ. Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. Int J Obes Relat Metab Disord. 1998;22:619–23.
18. Sibutramine for obesity. Med Lett Drugs Ther. 1998;40:32.
19. Proietto J. Anti-obesity drugs. Med J Aust. 1998;168:409–12.
20. Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord. 1998;22(suppl 1):S18–28.
21. Bach DS, Rissanen AM, Mendel CM, Shepard G, Weinstein SP, Kelly F, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res. 1999;7:363–9.
22. Cole JO, Levin A, Beake B, Kaiser PE, Scheinbaum ML. Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines. J Clin Psychopharmacol. 1998;18:231–6.
23. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352:167–72.
24. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. [Published erratum appears in JAMA 1999;281: 1174]. JAMA. 1999;281:235–42.
25. Jensen MD. Medical management of obesity. Semin Gastrointest Dis. 1998;9:156–62.
26. Lean MEJ. Obesity—what are the current treatment options? Exp Clin Endocrinol Diabetes. 1998;106(suppl 2):22–6.
Richard W. Sloan, M.D., R.Ph., coordinator of this series, is chairman and residency program director of the Department of Family Medicine at York (Pa.) Hospital and clinical associate professor in family and community medicine at the Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pa.
Copyright © 2000 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions